The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia
Open accessAbstract
BACKGROUND: The provision of sufficient basal insulin to normalize fasting plasma glucose levels may reduce cardiovascular events, but such a possibility has not been formally tested. METHODS: We randomly assigned 12,537 people (mean age, 63.5 years) with cardiovascular risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes to receive insulin glargine (with a target fasting blood glucose level of ≤95 mg per deciliter [5.3 mmol per liter]) or standard care and to receive n-3 fatty acids or placebo with the use of a 2-by-2 factorial design. The results of the comparison between insulin glargine and standard care are reported here. The coprimary outcomes were nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes and these events plus revascularization or hospitalization for heart failure. Microvascular outcomes, incident diabetes, hypoglycemia, weight, and cancers were also compared between groups. RESULTS: The median follow-up was 6.2 years (interquartile range, 5.8 to 6.7). Rates of incident cardiovascular outcomes were similar in the insulin-glargine and standard-care groups: 2.94 and 2.85 per 100 person-years, respectively, for the first coprimary outcome (hazard ratio, 1.02; 95% confidence interval [CI], 0.94 to 1.11; P=0.63) and 5.52 and 5.28 per 100 person-years, respectively, for the second coprimary outcome (hazard ratio, 1.04; 95% CI, 0.97 to 1.11; P=0.27). New diabetes was diagnosed approximately 3 months after therapy was stopped among 30% versus 35% of 1456 participants without baseline diabetes (odds ratio, 0.80; 95% CI, 0.64 to 1.00; P=0.05). Rates of severe hypoglycemia were 1.00 versus 0.31 per 100 person-years. Median weight increased by 1.6 kg in the insulin-glargine group and fell by 0.5 kg in the standard-care group. There was no significant difference in cancers (hazard ratio, 1.00; 95% CI, 0.88 to 1.13; P=0.97). CONCLUSIONS: When used to target normal fasting plasma glucose levels for more than 6 years, insulin glargine had a neutral effect on cardiovascular outcomes and cancers. Although it reduced new-onset diabetes, insulin glargine also increased hypoglycemia and modestly increased weight. (Funded by Sanofi; ORIGIN ClinicalTrials.gov number, NCT00069784.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both insulin glargine U100 and insulin degludec have demonstrated cardiovascular safety in dedicated CVOTs (207,208).”
From Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2022) · cites this paper as [208]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There are a number of other trials regarding cardiovascular outcomes in high-risk cohorts of patients with type 2 diabetes in which similar magnitude effects on glycemic control have been shown but without significant benefits with respect to rates of cardiovascular events or death.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“ORIGIN reported a 1.6 kg gain over 6 years with insulin glargine [46].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [46]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Modest survival benefits also have been reported for breast, ovarian, endometrial, prostate, lung, kidney, liver, and earlier stage pancreatic cancers.1791–1800”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1800]
Experimental — accuracy not yet measuredIn the citing paper
“The following drug classes were excluded due to lack of current evidence of efficacy in cardiovascular outcome trials: dipeptidyl peptidase-4 inhibitors,19 sulfonylureas,20 and insulin.21,22”
From Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis (2025) · cites this paper as [21]
In the citing paper
“It is associated with a lower risk of death and HF hospitalization compared with insulin and sulphonylureas in observational studies, though dedicated randomized, controlled, CVOTs evaluating safety and efficacy of metformin have not been conducted.[555][556][557]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [555]
In the citing paper
“It is associated with a lower risk of death and HF hospitalization compared with insulin and sulphonylureas in observational studies, though dedicated randomized, controlled, CVOTs evaluating safety and efficacy of metformin have not been conducted.[555][556][557]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [555]
In the citing paper
“These trials have more or less uniformly demonstrated a benefit, with lifestyle more efficacious than all medications with the exception of the thiazolidinediones140–152.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [146]
In the citing paper
“In the only RCT of insulin vs. placebo [ORIGIN, 12 537 people with CV risk factors plus impaired fasting glucose, impaired glucose tolerance, or T2DM (i.e.not in patients with HF)], insulin was not associated with higher rates of HF hospitalization than placebo.187”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [187]
In the citing paper
“Lowering glucose without addressing the vascular effects of insulin resistance may be insufficient to reduce risk of cardiovascular events.”
From The Vasculature in Prediabetes (2018) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726
Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults
Selvin, E., Steffes, M. W., Zhu, H., Matsushita, K., Wagenknecht, L., Pankow, J., Coresh, J., & Brancati, F. L. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908359 · Cited by 1,544
Flagged first, then by citations
Research works printed but not linked: 1
- Gerstein H, 2008, Am Heart J, 155, 26
Cited by
Sorted by citations
Items 601–700 of 999
Nassif, M. E., & Kosiborod, M. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.10.025 · Cited by 20
Vaduganathan, M., Inzucchi, S. E., Sattar, N. A., FITCHETT, D. H., Ofstad, A. P., Brueckmann, M., George, J. T., Verma, S., Mattheus, M., Wanner, C., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14535 · Cited by 21
Cheng, A. Y. Y., Wong, J., Freemantle, N., Acharya, S. H., & Ekinci, E. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00925-8 · Cited by 20
Charbonnel, B. H., Schweizer, A., & Dejager, S. (2013) · Hospital Practice · doi:10.3810/hp.2013.04.1059 · Cited by 20
The cardiovascular effects of insulin
Younk, L. M., Lamos, E. M., & Davis, S. N. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.919256 · Cited by 20
Milligan, S. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.03.010 · Cited by 20
Schernthaner, G., Cahn, A., & Raz, I. (2016) · Diabetes Care · doi:10.2337/dcs15-3009 · Cited by 20
Zheng, C., Xuan, W., Chen, Z., Zhang, R., Huang, X., Zhu, Y., Ma, S., Chen, K., Chen, L., He, M., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.848310 · Cited by 20
Retnakaran, R. R., Ye, C., Emery, A., Kramer, C. K., & Zinman, B. (2022) · Nature Communications · doi:10.1038/s41467-022-33867-9 · Cited by 20
Caring for Patients With Diabetes in Stroke Neurology
Kernan, W. N., Forman, R., & Inzucchi, S. E. (2022) · Stroke · doi:10.1161/strokeaha.122.038163 · Cited by 23
Temas de actualidad en cardiología: riesgo vascular y rehabilitación cardiaca
Galve, E., Castro, A., Cordero, A., Dalmau, R., Fácila, L., García-Romero, A., Mazón, P., Sanmartı́n, M., & Garcia, A. A. (2012) · Revista Española de Cardiología · doi:10.1016/j.recesp.2012.10.009 · Cited by 20
Insulin Therapy and Cancer in Type 2 Diabetes
Mannucci, E. (2012) · ISRN Endocrinology · doi:10.5402/2012/240634 · Cited by 21
Wong, A. T. Y., Chan, D. C., Ooi, E. M. M., Ng, T. W., Watts, G. F., & Barrett, P. H. R. (2013) · Clinical Science · doi:10.1042/cs20120587 · Cited by 20
Risk of Breast Cancer by Individual Insulin Use: An International Multicenter Study
Grimaldi‐Bensouda, L., Cameron, D., Marty, M. E., Barnett, A. H., Penault-Llorca, F. M., Pollak, M., Charbonnel, B. H., Riddle, M. C., Mignot, L., Boivin, J., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0695 · Cited by 20
Update in Cardiology: Vascular Risk and Cardiac Rehabilitation
Galve, E., Alegría, E., Cordero, A., Fácila, L., de Bobadilla, J. F., Lluís-Ganella, C., Mazón, P., Zarzosa, C. D. P., & González‐Juanatey, J. R. (2014) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2013.09.019 · Cited by 20
Clinical Implications of Cardiovascular Outcome Trials in Type 2 Diabetes: From DCCT to EMPA-REG
Rydén, L., Shahim, B., & Mellbin, L. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.03.035 · Cited by 20
Insulin glargine use and breast cancer risk: Associations with cumulative exposure
Peeters, P. J. H. L., Bazelier, M. T., Leufkens, H. G. M., Auvinen, A. P., van Staa, T. P., de Vries, F., & Bruin, M. L. D. (2016) · Acta Oncologica · doi:10.3109/0284186x.2016.1155736 · Cited by 22
The EMPA-REG outcome study: critical appraisal and potential clinical implications
Perseghin, G., & Solini, A. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0403-8 · Cited by 20
Mostafa, S. A., Coleman, R. L., Agbaje, O. F., Gray, A. M., Holman, R. R., & Bethel, M. A. (2017) · Diabetic Medicine · doi:10.1111/dme.13533 · Cited by 22
Hinton, W., Feher, M. D., Munro, N. M., Walker, M., & de Lusignan, S. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13710 · Cited by 19
Glargine-300: An updated literature review on randomized controlled trials and real-world studies
Ghosh, S. K., & GHOSH, R. (2020) · World Journal of Diabetes · doi:10.4239/wjd.v11.i4.100 · Cited by 20
How Diabetes and Heart Failure Modulate Each Other and Condition Management
Randhawa, V. K., Dhanvantari, S., & Connelly, K. A. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.11.014 · Cited by 20
Hanefeld, M., Fleischmann, H., Schiffhorst, G., & Bramlage, P. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0246 · Cited by 20
Anyanwagu, U., Mamza, J., Donnelly, R., & IDRIS, I. R. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.09.002 · Cited by 20
Diabetic cardiomyopathy revisited: The interplay between diabetes and heart failure
Mann, C., Braunwald, E., & Zelniker, T. A. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133554 · Cited by 23
Davenport, C., Mahmood, W. A. W., Forde, H. E., Ashley, D. T., Agha, A., McDermott, J., Sreenan, S., Thompson, C. J., McGrath, F. P., McAdam, B. F., et al. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-1137 · Cited by 19
Cancer Specific Mortality in Insulin-Treated Type 2 Diabetes Patients
Ioacără, S., Guja, C., Ionescu-Tirgoviste, C., Fica, S. V., & Roden, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093132 · Cited by 18
Luconi, M., Raimondi, L., Franco, A. D., & Mannucci, E. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.09.001 · Cited by 19
Practical combination therapy based on pathophysiology of type 2 diabetes
LEVIN, P. A. (2016) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s109216 · Cited by 21
Type 2 diabetes and cancer: problems and suggestions for best patient management
Milluzzo, A., Vigneri, P. G., Martorana, F., Vigneri, R., & Sciacca, L. (2020) · Exploration of Medicine · doi:10.37349/emed.2020.00013 · Cited by 19
Mert, K. U., Başaran, Ö., Mert, G. Ö., Doğan, V., Rencüzoğulları, İ., Özlek, B., Çinier, G., Şenol, U., Çelik, O., Özlek, E., et al. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13528 · Cited by 19
Methylene-bridge tryptophan fatty acylation regulates PI3K-AKT signaling and glucose uptake
Hu, S., He, X., Nie, J., Hou, J., Wu, J., Liu, X., Wei, Y., Tang, H., Sun, W.-X., Zhou, S.-X., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110509 · Cited by 20
Artificial Intelligence in Efficient Diabetes Care
Khodve, G., & Banerjee, S. (2022) · Current Diabetes Reviews · doi:10.2174/1573399819666220905163940 · Cited by 19
Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes
Conde, A. C., Martín, D. M., Ruíz, R. C., Olmo, M. R. F., Ariño, C. M., Gómez‐Doblas, J. J., Górriz, J. L., Mazón‐Ramos, P., García–Moll, X., Soler, M. J., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12123925 · Cited by 22
Guthrie, R. M. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.05.2654 · Cited by 19
Mata‐Cases, M., Artola, S., Escalada, J., Loiola, P. E., Ferrer-García, J. C., Fornos, J. A., Girbés, J., & Rica, I. (2015) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2014.10.001 · Cited by 19
Insulin Analogs and Cancer: A Note of Caution
Janssen, J. A. M. J. L., & Varewijck, A. J. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00079 · Cited by 19
Jorsal, A., Wiggers, H., & McMurray, J. J. V. (2017) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.007 · Cited by 20
The Evolving Epidemiology of Atherosclerotic Cardiovascular Disease in People with Diabetes
Pasquel, F. J., Gregg, E. W., & Ali, M. K. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.11.001 · Cited by 20
Fagg, J., & Valabhji, J. (2018) · Diabetic Medicine · doi:10.1111/dme.13867 · Cited by 20
Diabetes Care Editors’ Expert Forum 2018: Managing Big Data for Diabetes Research and Care
Riddle, M. C., Blonde, L., Gerstein, H. C., Gregg, E. W., Holman, R. R., Lachin, J. M., Nichols, G. A., Turchin, A., & Cefalu, W. T. (2019) · Diabetes Care · doi:10.2337/dci19-0020 · Cited by 21
Mendez, C. E., Walker, R. J., Eiler, C., Mishriky, B. M., & Egede, L. E. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1643635 · Cited by 19
Shao, H., Yang, S., Stoecker, C., Fonseca, V. A., Hong, D., & Shi, L. (2019) · Value in Health · doi:10.1016/j.jval.2019.08.007 · Cited by 19
The Changing Landscape of Pharmacotherapy for Diabetes Mellitus: A Review of Cardiovascular Outcomes
Wu, L., & Gunton, J. E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235853 · Cited by 19
Chazova, I. E., Shestakova, M. V., Zhernakova, Y. V., Blinova, N. V., Маркова, Т. Н., Mazurina, N. V., Владиславович, Е. М., Tereshchenko, S. N., Жиров, И. В., Komarov, A. L., et al. (2021) · Eurasian heart journal · doi:10.38109/2225-1685-2021-2-6-61 · Cited by 19
Katz, P. M., Leiter, L. A., Mellbin, L., & Rydén, L. (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114546854 · Cited by 19
Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glargine 300 U/mL
Clements, J. N., Threatt, T. B., Ward, E. D., & Shealy, K. M. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0464-6 · Cited by 19
Gerstein, H. C., Paré, G., McQueen, M., Lee, S. F., Hess, S., & for ORIGIN Trial Investigators (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00273 · Cited by 18
Targeting beta-cell preservation in the management of type 2 diabetes
Boughton, C. K., Munro, N. M., & Whyte, M. (2017) · British Journal of Diabetes · doi:10.15277/bjd.2017.148 · Cited by 21
Diabetes and cardiovascular disease in older adults
Bilal, A., & Pratley, R. E. (2024) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15259 · Cited by 18
Jansen, H., Lieb, W., & Schunkert, H. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6640-y · Cited by 19
Shaefer, C. F., Reid, T., DAILEY, G. E., Mabrey, M., Vlajnic, A., Stuhr, A., Stewart, J. A., & Zhou, R. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.10.2824 · Cited by 18
ter Braak, B., Siezen, C. L. E., Kannegieter, N. M., Koedoot, E., van de Water, B., & van der Laan, J. W. (2014) · Archives of Toxicology · doi:10.1007/s00204-014-1201-2 · Cited by 18
Glargine safety, diabetes and cancer
Rendell, M., Aktürk, H. K., & Tella, S. H. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.770469 · Cited by 18
Zhang, X., Liu, Y., Zhang, F., Li, J., & Tong, N. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.03.015 · Cited by 18
Cardiovascular outcomes and safety with antidiabetic drugs.
Aldossari, K. K. (2018) · Europe PMC (PubMed Central) · Cited by 18
Brown‐Frandsen, K., Emerson, S. S., McGuire, D. K., Pieber, T. R., Poulter, N. R., Pratley, R. E., Zinman, B., Ranthe, M. F., Grøn, R., Lange, M., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13677 · Cited by 18
Insulin Therapy for Pre-Hyperglycemic Beta-Cell Endoplasmic Reticulum Crowding
Absood, A., Gandomani, B. S., Zaki, A. L., Nasta, V., Michail, A., Habib, P. M. W., & Hodish, I. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054351 · Cited by 18
Advances in Pharmacologic Therapies for Type 2 Diabetes
Morsink, L. M., Smits, M. M., & Diamant, M. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0302-8 · Cited by 18
Herrmann, K., Zhou, M., Wang, A., & de Bruin, T. W. (2016) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-016-0030-z · Cited by 18
Challenges and unmet needs in basal insulin therapy: lessons from the Asian experience
Chan, W. B., Chen, J.-F., Goh, S., Vũ, T. T. H., Isip-Tan, I. T., Mudjanarko, S. W., Bajpai, S., Mabunay, M. A., & Bunnag, P. (2017) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s143046 · Cited by 18
Update on Management of Type 2 Diabetes for Cardiologists
Qureshi, M., Gammoh, E., Shakil, J., & Robbins, R. J. (2018) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-14-4-273 · Cited by 17
Lizarzaburu-Robles, J. C., Herman, W. H., Garro-Mendiola, A., Sanz-Pastor, A. G., & Lorenzo, Ó. (2024) · Biomedicines · doi:10.3390/biomedicines12020363 · Cited by 17
Galis, P., Bartosova, L., Farkašová, V., Barteková, M., Ferenczyová, K., & Rajtík, T. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1451100 · Cited by 19
Valensi, P. E. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02436-3 · Cited by 21
Rydén, L., estable, G. D. T. D. L. S. E. D. C. S. D. Y. T. D. L. C. I., Grant, P. J., Anker, S. D., Berne, C., Cosentino, F., Danchin, N., Deaton, C., Escaned, J., Hammes, H. P., et al. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2013.10.015 · Cited by 20
Valenzuela-García, L. F., Matsuzawa, Y., Sara, J. D. S., Kwon, T., Lennon, R. J., Lerman, L. O., Ruiz-Salmeron, R. J., & Lerman, A. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0269-1 · Cited by 17
DPP-4 inhibitors, heart failure and type 2 diabetes: all eyes on safety.
Paneni, F. (2015) · PubMed Central · doi:10.3978/j.issn.2223-3652.2015.09.06 · Cited by 17
Reducing cardiovascular disease risk in type 2 diabetes: is the focus on glycaemia warranted?
Ferguson, L. D., & Sattar, N. A. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12018 · Cited by 16
Personalized Therapy by Phenotype and Genotype
Lyssenko, V., Bianchi, C., & Prato, S. D. (2016) · Diabetes Care · doi:10.2337/dcs15-3002 · Cited by 19
Vedtofte, L., Knop, F. K., & Vilsbøll, T. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1288715 · Cited by 17
Burggraaf, B., & Cabezas, M. C. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.04.017 · Cited by 17
Bataille, V., Ferrières, J., Danchin, N., Puymirat, É., Zeller, M., Simon, T., & Carrié, D. (2017) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872617719639 · Cited by 17
Insulin Centennial: Milestones influencing the development of insulin preparations since 1922
Owens, D. R., Monnier, L., Ceriello, A., & Bolli, G. B. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14587 · Cited by 17
Temas de actualidad en cardiología: riesgo vascular y rehabilitación cardiaca
Galve, E., Alegría, E., Cordero, A., Fácila, L., de Bobadilla, J. F., Lluís-Ganella, C., Mazón, P., Zarzosa, C. D. P., & González‐Juanatey, J. R. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2013.09.021 · Cited by 18
Ferrannini, E., Baldi, S., Scozzaro, T., Tsimihodimos, V., Tesfaye, F., Shaw, W. C., Rosenthal, N. R., Figtree, G. A., Neal, B. C., Mahaffey, K. W., et al. (2022) · Diabetes Care · doi:10.2337/dc21-2398 · Cited by 19
Insulin therapy in insulin resistance: Could it be part of a lethal pathway?
Bittencourt, M. S., & Hajjar, L. A. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.04.013 · Cited by 17
Baričević-Jones, I., Jones, D. R., Roberts, D. L., Lützen, A., Lundby, A., Worm, J., Hansen, B. F., & Renehan, A. G. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv071 · Cited by 18
Drab, S. R., & Philis‐Tsimikas, A. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1361 · Cited by 17
Insulin glargine 300 units/mL: A new basal insulin product for diabetes mellitus
Clements, J. N., & Bello, L. (2016) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp150174 · Cited by 17
Chengji, W., & Xian-jin, F. (2018) · Endocrine Connections · doi:10.1530/ec-18-0060 · Cited by 17
Wang, A., Arver, S., Boman, K., Gerstein, H. C., Lee, S. F., Hess, S., Rydén, L., & Mellbin, L. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318819142 · Cited by 17
Insulin and cardiovascular disease: biomarker or association?
Jandeleit-Dahm, K. A. M., & Gray, S. P. (2012) · Diabetologia · doi:10.1007/s00125-012-2729-4 · Cited by 18
A dysglycaemic effect of statins in diabetes: relevance to clinical practice?
Swerdlow, D. I., & Sattar, N. A. (2014) · Diabetologia · doi:10.1007/s00125-014-3409-3 · Cited by 17
The obesity paradox in secondary prevention: a weighty intervention or a wait for more evidence?
Sattar, N. A., & Welsh, P. I. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa398 · Cited by 17
The Dramatic Spread of Diabetes Mellitus Worldwide and Influence of Helicobacter pylori
Nasrat, S. A. (2014) · General Medicine Open Access · doi:10.4172/2327-5146.1000159 · Cited by 16
Scholz, G. H., & Fleischmann, H. (2014) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814556099 · Cited by 16
Type 2 diabetes and cardiovascular prevention: the dogmas disputed
Giugliano, D., Maiorino, M. I., Bellastella, G., & Esposito, K. (2017) · Endocrine · doi:10.1007/s12020-017-1418-y · Cited by 16
The effects of antidiabetic agents on heart failure
Wijnen, M., Duschek, E. J. J., Boom, H., & van Vliet, M. (2021) · Netherlands Heart Journal · doi:10.1007/s12471-021-01579-2 · Cited by 17
Heart failure and diabetes: Clinical significance and epidemiology of this two‐way association
Jerkins, T. W., McGill, J. B., & Bell, D. S. H. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15062 · Cited by 19
Insulin Hypersecretion as Promoter of Body Fat Gain and Hyperglycemia
Mittendorfer, B., Johnson, J. D., Solinas, G., & Jansson, P. (2024) · Diabetes · doi:10.2337/dbi23-0035 · Cited by 18
Xu, W., & Weng, J. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12054 · Cited by 15
A Review of Cardiovascular Outcomes in the Treatment of People with Type 2 Diabetes
DAILEY, G. E., & Wang, E. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0091-x · Cited by 16
Empagliflozin as a new management strategy on outcomes in patients with type 2 diabetes mellitus
Салухов, В. В., & Demidova, T. Y. (2016) · Diabetes Mellitus · doi:10.14341/dm8216 · Cited by 17
Packer, M. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13191 · Cited by 15
Peralta, F. G., Martín, F. J. E. S., Torre, E. L. M., Mata‐Cases, M., García, J. C. F., Loiola, P. E., Lachica, L. Á., Pérez, J. A. F., Menéndez, S. A., Guisasola, F. Á., et al. (2018) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2018.11.010 · Cited by 16
Personalized Management of Type 2 Diabetes
Peter, P. R., & Lupsa, B. C. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1244-0 · Cited by 16
Balletshofer, B. M., Ito, W. D., Lawall, H., Malyar, N. M., Oberländer, Y., Reimer, P., Rittig, K., & Zähringer, M. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1018-9250 · Cited by 18
Lefever, E., Vliebergh, J., & Mathieu, C. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1856813 · Cited by 16
Butler‐Laporte, G., Nakanishi, T., Mooser, V., Renieri, A., Amitrano, S., Zhou, S., Chen, Y., Forgetta, V., & Richards, J. B. (2020) · International Journal of Epidemiology · doi:10.1093/ije/dyaa229 · Cited by 16
Metadata
- Authors
- The ORIGIN Trial Investigators
- Affiliations
- Population Health Research Institute (CA)
- Corresponding author
- The ORIGIN Trial Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-07-26
- Volume
- 367
- Issue
- 4
- Pages
- 319-328
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1975663485
- Semantic Scholar
- 695c6a8e398d66ae418b143a3491ad91d28443bb
- Cited by
- 1,636
- References
- 29
- Citations by year
- 2026: 34 · 2025: 41 · 2024: 76 · 2023: 86 · 2022: 82 · 2021: 108 · 2020: 101 · 2019: 139 · 2018: 155 · 2017: 152 · 2016: 155 · 2015: 132 · 2014: 168 · 2013: 147 · 2012: 53
- FWCI
- 128.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Monash University Research Portal (Monash University) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- HAL (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- IRIS (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- University of Oxford
- AFA Försäkring
- Hjärt-Lungfonden
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- basal insulin, insulin glargine, impaired fasting glucose, impaired glucose tolerance, type 2 diabetes, cardiovascular outcomes, myocardial infarction, stroke, heart failure, omega-3 fatty acids, hypoglycemia, weight gain, cancer risk, microvascular outcomes, cardiovascular risk factors, revascularization, hospitalization, new-onset diabetes
- MeSH terms
- Insulin Glargine, Aged, Blood Glucose, Cardiovascular Diseases, Cholesterol, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Fasting, Female, Follow-Up Studies, Hospitalization, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Middle Aged, Triglycerides, Fatty Acids, Omega-3, Incidence, Proportional Hazards Models, Glucose Intolerance, Insulin, Long-Acting, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
